Table 5 HRCT findings of included cases before and after the administration of mesenchymal stem cells
Pt. no | HRCT findings (months) |
|---|---|
1 | − 2: PM and thin fibrotic bands in LUL 0: PM, PP, and SE (suggestive of cGVHD) + 6: Bilateral lung hyperaeration, bronchiectasis, and PT + 12: Mild hyperaeration, bronchiectasis, and PT |
2 | − 5: PT and bilateral GGOs at the middle and inferior lung portions + 5: Mild, central bronchiectasis |
3 | 0: Moderate and diffuse bronchiectasis and lung hyperaeration + 4: Mild, bilateral bronchiectasis and lung hyperaeration, mild PM, PP, and SE, and a thin-walled cavity at the upper pole of RLL; 2 and 4 weeks later, progression of PM, PP, and SE was noted (possibly due to underlying COVID-19) + 18: Same, without obvious progression or resolution of abnormalities |
4 | − 3: Bilateral PT and hyperaeration, with minimal MA (in favor of bronchitis) 0: Diffuse bilateral MA with UL predilection, in favor of cGVHD + 1: MA and patchy GGOs in both lungs, diffuse PT, and mild bronchiectasis, probably due to COVID-19; subsequent images taken 2 weeks later showed mild bronchiectatic changes in both LLs + 4: Diffuse hyperaeration, MA, bronchiectasis, bronchial thickening, mucus plugs, and GGOs in both ULs + 6: LL dominant bronchiectatic changes and MA* in both lungs, mucus plaque formation, and an 11 × 11 mm pneumatocele in RUL with thin adjacent fibrotic bands (all in favor of cGVHD) + 12: Bronchiectatic changes, bronchial wall thickening, scattered centriacinar nodules, and MA* in both lungs + 20: Cylindrical bronchiectasis in both LLs with some bronchoceles and MA in both lungs |